# Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

> **NCT07101094** · — · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 300 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** xanomeline and trospium chloride (X/T) therapy

## Key facts

- **NCT ID:** NCT07101094
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-22
- **Primary completion:** 2029-01-31
- **Final completion:** 2029-05-14
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07101094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07101094, "Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07101094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*